Avid Bioservices - CDMO Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDMO shares.
View CDMO analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price objectives for Avid Bioservices' stock. Their CDMO share price forecasts range from $20.00 to $28.00. On average, they predict the company's share price to reach $24.33 in the next twelve months. This suggests a possible upside of 86.6% from the stock's current price.
View analysts price targets for CDMO or view top-rated stocks among Wall Street analysts.

Avid Bioservices' stock was trading at $29.18 at the beginning of 2022. Since then, CDMO stock has decreased by 55.3% and is now trading at $13.04.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our CDMO earnings forecast.

Avid Bioservices, Inc. (NASDAQ:CDMO) issued its earnings results on Tuesday, December, 7th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.04. The biopharmaceutical company had revenue of $26.11 million for the quarter, compared to analysts' expectations of $25 million. Avid Bioservices had a trailing twelve-month return on equity of 3.56% and a net margin of 88.13%. During the same quarter in the prior year, the firm earned $0.01 EPS.

Avid Bioservices shares reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Avid Bioservices issued an update on its FY 2023 earnings guidance on Tuesday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $145.00 million-$150.00 million, compared to the consensus revenue estimate of $143.81 million.

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Avid Bioservices' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.53%), Vanguard Group Inc. (6.79%), State Street Corp (6.24%), Jennison Associates LLC (4.63%), Geneva Capital Management LLC (2.32%) and Artisan Partners Limited Partnership (1.84%). Insiders that own company stock include Daniel R Hart, Daniel Ryan Hart, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends.

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDMO stock can currently be purchased for approximately $13.04.

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $810.70 million and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.69 on an earnings per share basis.

The company employs 252 workers across the globe.

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for the company is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.